Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2019, 5354320

Factors Influencing Disability and Quality of Life During Treatment: A Cross-Sectional Study on IBD Patients


Factors Influencing Disability and Quality of Life During Treatment: A Cross-Sectional Study on IBD Patients

Carla Marinelli et al. Gastroenterol Res Pract.


Background/aim: Inflammatory bowel disease (IBD) is a chronic disorder affecting patients' quality of life and increasing their disability. The aim of our study was to evaluate clinical and pharmacological factors associated with impaired quality of life and disability in a large cohort of IBD patients during IBD treatment.

Methods: We consecutively and prospectively recruited all IBD patients referred to the IBD Unit of the "Azienda Ospedaliera" of Padua. Demographics and clinical information were collected, and all patients completed the IBD questionnaire (IBDQ) and the IBD-Disability Index (IBD-DI) questionnaire. A multivariate regression model and Spearman's rank correlation coefficient were applied for detecting IBD-related variables relevant to disability and quality of life.

Results: We included 435 IBD patients. Multivariate regression modelling identified active disease, anaemia, presence of extraintestinal manifestations, and Crohn subtype as independent predictors for both disability and poor quality of life. We observed a strong positive correlation between IBD-DI and IBDQ (r = 0.84, p < 0.001), while there was no association with ongoing therapy or other clinical features disease-related.

Conclusions: Our study showed that disability and quality of life are both associated with active disease, anaemia, presence of extraintestinal manifestations, and Crohn phenotype while ongoing therapy seems not to be associated with disability and QoL during disease management.

Conflict of interest statement

None of the authors declared any conflicts of interest or disclosed any financial relationship relevant to this publication.


Figure 1
Figure 1
Spearman correlation between IBDQ and IBD-DI scores.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles


    1. Aggarwal A., Sabol T., Vaziri H. Update on the use of biologic therapy in ulcerative colitis. Current Treatment Options in Gastroenterology. 2017;15(1):155–167. doi: 10.1007/s11938-017-0120-8. - DOI - PubMed
    1. Guo B.-J., Bian Z. X., Qiu H. C., Wang Y. T., Wang Y. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. Annals of the New York Academy of Sciences. 2017;1401(1):37–48. doi: 10.1111/nyas.13414. - DOI - PubMed
    1. Irvine J. E. Quality of life of patients with ulcerative colitis: past, present, and future. Inflammatory Bowel Diseases. 2008;14(4):554–565. doi: 10.1002/ibd.20301. - DOI - PubMed
    1. Lo B., Julsgaard M., Vester-Andersen M. K., Vind I., Burisch J. Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study. European Journal of Gastroenterology & Hepatology. 2018;30(10):1130–1136. doi: 10.1097/MEG.0000000000001199. - DOI - PubMed
    1. Allen P. B., Gower-Rousseau C., Danese S., Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 2017;10(11):865–876. doi: 10.1177/1756283X17732720. - DOI - PMC - PubMed

LinkOut - more resources